Background: Internet-based cognitive behavioral therapy can aid patients with rheumatoid arthritis with elevated levels of distress to enhance their quality of life. However, implementation is currently lacking and there is little evidence available on the (cost-) effectiveness of different treatment strategies.
Objective: Cost-benefit ratios are necessary for informing stakeholders and motivating them to implement effective treatment strategies for improving health-related quality of life (HRQoL) of patients with rheumatoid arthritis. A cost-effectiveness study from a societal perspective was conducted alongside a randomized controlled trial on a tailored, therapist-guided internet-based cognitive behavioral therapy (ICBT) intervention for patients with rheumatoid arthritis with elevated levels of distress as an addition to care as usual (CAU).
Methods: Data were collected at baseline or preintervention, 6 months or postintervention, and every 3 months thereafter during the 1-year follow-up. Effects were measured in terms of quality-adjusted life years (QALYs) and costs from a societal perspective, including health care sector costs (health care use, medication, and intervention costs), patient travel costs for health care use, and costs associated with loss of labor.
Results: The intervention improved the quality of life compared with only CAU (Δ QALYs=0.059), but at a higher cost (Δ=€4211). However, this increased cost substantially reduced when medication costs were left out of the equation (Δ=€1863). Of all, 93% (930/1000) of the simulated incremental cost-effectiveness ratios were in the north-east quadrant, indicating a high probability that the intervention was effective in improving HRQoL, but at a greater monetary cost for society compared with only CAU.
Conclusions: A tailored and guided ICBT intervention as an addition to CAU for patients with rheumatoid arthritis with elevated levels of distress was effective in improving quality of life. Consequently, implementation of ICBT into standard health care for patients with rheumatoid arthritis is recommended. However, further studies on cost reductions in this population are warranted.
Trial Registration: Nederlands Trial Register NTR2100; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2100 (Archived by WebCite at http://www.webcitation.org/724t9pvr2).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231867 | PMC |
http://dx.doi.org/10.2196/jmir.9997 | DOI Listing |
Front Immunol
January 2025
Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the impact of IMID on the immune response to (Mtb) in patients with TBI and TB disease.
Methods: We enrolled TBI and TB patients with and without IMID.
Eur Cardiol
December 2024
REMEDY Center for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital Oslo, Norway.
This review examines the cardiovascular risks associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), both traditional NSAIDs and cyclooxygenase-2 selective inhibitors (COXIBs). It describes the history of traditional NSAIDs and the development of COXIBs to explain why their cardiovascular side effects were unnoticed for many decades. Further, the review presents the mechanism of action of NSAIDs, to elucidate the possible underlying basis for why they are associated with an increased risk of cardiovascular disease.
View Article and Find Full Text PDFJSES Rev Rep Tech
February 2025
Clinique Claude Bernard, Unité de Chirurgie Orthopédique, Metz, France.
Background: The importance of the subscapularis for reverse total shoulder arthroplasty has been demonstrated, especially for internal rotation and stability. In a deltopectoral approach, a detachment of the subscapularis is performed (tenotomy, tuberosity peeling, or osteotomy), but the tendon is not always repairable at the end. When it is repaired, healing is obtained in only 40%-76% of the cases, with potential consequences for the outcomes.
View Article and Find Full Text PDFCurr Rheumatol Rev
January 2025
Department of Pharmaceutical Chemistry, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur (MS), India.
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires early detection and treatment. Currently, we have three categories of slow-acting disease-modifying antirheumatic drugs (DMARDs): (1) conventional synthetic (csDMARD), (2) biologic (bDMARD), and (3) directed or targeted synthetic (tsDMARD).
Objective: This review explores innovative therapeutic modalities for RA, discussing their potential advantages and challenges.
Adv Rheumatol
January 2025
Reumavance Group, Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.
Background: To date, there has been limited exploration, particularly on a national scale, of the prevalence patterns of comorbidities and complications associated with rheumatoid arthritis (RA) in Colombia. We aimed to analyze the prevalence patterns of comorbidities and disease-related complications of RA patients enrolled in Colombia's contributory healthcare regime.
Methods: We performed a nationwide observational descriptive cross-sectional study using administrative claims data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!